At the end of 2014, the Company obtained the domestic production license of Onko-Sure DR-70 tumor marker, and will expand the domestic sales business this year, and plans to complete the listing of major countries in Asia and the Pacific (Japan, South Korea, Australia, New Zealand, ASEAN countries, China to Turkey and other countries) within three years, and enter the regional market and even the global market beyond the domestic market.
Uni Pharma, in combination with a number of expert consultants and research units, uses the latest technology to continuously improve Onko-Sure DR-70, and expects to develop the second generation of rapid screening products or more accurate Bead Assay products, and Huayu is also about to carry out the research and development of the third generation of combo reagents combining Onko-Sure and other tumor markers, and will obtain exclusive protection and exclusive rights for these products in the future.
